Login / Signup
Immunotherapy plus chemotherapy showed superior clinical benefit to chemotherapy alone in advanced NSCLC patients after progression on osimertinib.
Yaping Long
Qi Xiong
Qi Song
Yao Li
Xiaoyan Li
Boyu Qin
Ziwei Huang
Yi Hu
Bo Yang
Published in:
Thoracic cancer (2021)
Our study provides the clinical evidence of favoring immunotherapy plus chemotherapy in NSCLC patients after progression on osimertinib.
Keyphrases
</>
small cell lung cancer
end stage renal disease
advanced non small cell lung cancer
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
locally advanced
epidermal growth factor receptor
squamous cell carcinoma
patient reported outcomes
radiation therapy
rectal cancer
chemotherapy induced